الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - trogarzo, koos muu retroviirusevastase(s), on näidustatud ravi täiskasvanud nakatunud multidrug resistentse hiv-1 nakkus, kelle puhul on muul viisil ei ole võimalik luua pärssivat viirusevastane raviskeemi.

أستونيا - الإستونية - Ravimiamet

zentiva k.s. - fulvestrant - süstelahus süstlis - 250mg 5ml 5ml 2tk; 250mg 5ml 5ml 1tk; 250mg 5ml 5ml 6tk; 250mg 5ml 5ml 4tk

أستونيا - الإستونية - Ravimiamet

ideal trade links uab - letrosool - õhukese polümeerikattega tablett - 2,5mg 30tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - asatsitidiin - leukeemia, müeloidne, äge - antineoplastilised ained - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

أستونيا - الإستونية - Ravimiamet

zentiva k.s. - abirateroon - õhukese polümeerikattega tablett - 500mg 56tk; 500mg 60tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

amgen europe bv - sotorasib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

أستونيا - الإستونية - Ravimiamet

viasana uab - abirateroon - õhukese polümeerikattega tablett - 500mg 56tk

أستونيا - الإستونية - Ravimiamet

stada arzneimittel ag - fulvestrant - süstelahus süstlis - 250mg 5ml 5ml 4tk; 250mg 5ml 5ml 1tk; 250mg 5ml 5ml 2tk; 250mg 5ml 5ml 6tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - muud närvisüsteemi ravimid - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.